
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is well-positioned for growth in the near- to medium-term with multiple upcoming catalysts, including initiation of Phase 3 trials and potential FDA approval for zanzalintinib in different tumor types. Despite missing in the NLM subset, the STELLAR-303 study supports the efficacy of zanzalintinib in combination with atezolizumab, and with strong demand for their current commercial portfolio, the company's future looks promising. It is estimated that Exelixis' revenue will increase by 32.4% in the next fiscal year and reach $2.71 billion in sales in 2025.
Bears say
Exelixis is facing several key risks that may impact its financial performance, including potential commercial risks with its lead drug Cabometyx, clinical trial risks with its pipeline candidates, generic erosion of existing franchises, and possible dilution risks from potential equity financings. In addition, the company operates in a highly competitive industry, which may limit its market share and impact its profitability. These factors, combined with the negative trends in its valuation and possible delays in regulatory approvals, contribute to a negative outlook on Exelixis's stock.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares